Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295657	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (11 years from now)
US9119876	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (11 years from now)
US10130592	PAR STERILE PRODUCTS	Epinephrine formulations	Mar, 2035 (11 years from now)

Adrenalin is owned by Par Sterile Products.

Adrenalin contains Epinephrine.

Adrenalin has a total of 3 drug patents out of which 0 drug patents have expired.

Adrenalin was authorised for market use on 07 December, 2012.

Adrenalin is available in solution;intramuscular, intravenous, subcutaneous dosage forms.

Adrenalin can be used as emergency treatment of allergic reactions (type i), including anaphylaxis.

The generics of Adrenalin are possible to be released after 13 March, 2035.

Market Authorisation Date: 07 December, 2012

Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/mL ampules	09 Mar, 2016	1	06 Jul, 2018	13 Mar, 2035	Deferred
30 mg/30 mL	20 Aug, 2018	1	24 Apr, 2020	13 Mar, 2035	Eligible

Strength	Dosage	Availability
EQ 1MG BASE/ML (EQ 1MG BASE/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	Prescription

ADRENALIN family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic